CJ Bioscience, Inc.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 2009-12-09
- Employees
- 137
- Market Cap
- -
- Website
- http://www.cjbioscience.com
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
Phase 1
Recruiting
- Conditions
- NSCLCHNSCCMelanomaAdvanced Solid TumorMetastatic CancerAdvanced Cancer
- Interventions
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- CJ Bioscience, Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT05877430
- Locations
- 🇺🇸
University of California, Irvine, Irvine, California, United States
🇰🇷Severance Hospital, Seoul, Korea, Republic of
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
© Copyright 2025. All Rights Reserved by MedPath